D-penicillamine in the neonatal period

Possible beneficial effects on the lethality of HIV infection due to vertical transmission

G. Balla, Lajos Lakatos, István Pataki, Zsuzsanna Vekerdy-Nagy, György Oroszlán

Research output: Contribution to journalArticle

Abstract

D-penicillamine (DPA) was first recognized as a potential benefit for neonatal hyperbilirubinemia (NHBI). During this time there was a remarkedly low incidence of retinopathy of prematurity (ROP) in the infants treated with DPA. Later, our studies were replicated in other institutes in Hungary, Poland, the U.S. A., India and Mexico. It is important to note that there was no intolerance or short- or long-term toxicity of the medication, in spite of the fact that in the newborn period DPA was used 10-20 times higher doses than those in adult. On the basis of an American research work concerning the beneficial effects of DPA-therapy in adult AIDS-patients (although in these cases there were many unpleasant, adverse effects), it would be reasonable to treat neonatal HIV-positivity due to vertical transmission with short-term DPA therapy (300 - 400 mg/kg/bw/day for 5-7 days). Therefore, we have a moral obligation to help the fight against HIV with this inexpensive (~ 30 USD/baby) drug in the neonatal period.

Original languageEnglish
Article number07
Pages (from-to)30-42
Number of pages13
JournalInternational Journal of Pharmaceutical Sciences Review and Research
Volume33
Issue number2
Publication statusPublished - Jul 1 2015

Fingerprint

Penicillamine
HIV Infections
Moral Obligations
Neonatal Hyperbilirubinemia
HIV
Retinopathy of Prematurity
Hungary
Poland
Mexico
India
Acquired Immunodeficiency Syndrome
Newborn Infant
Incidence
Therapeutics
Research
Pharmaceutical Preparations

Keywords

  • D-penicillamine
  • HIV/AIDS therapy
  • Neonatal hyperbilirubinemia
  • Retinopathy of prematurity

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

D-penicillamine in the neonatal period : Possible beneficial effects on the lethality of HIV infection due to vertical transmission. / Balla, G.; Lakatos, Lajos; Pataki, István; Vekerdy-Nagy, Zsuzsanna; Oroszlán, György.

In: International Journal of Pharmaceutical Sciences Review and Research, Vol. 33, No. 2, 07, 01.07.2015, p. 30-42.

Research output: Contribution to journalArticle

@article{a81e3c3c5dad4aed91ea9dd3ac58f302,
title = "D-penicillamine in the neonatal period: Possible beneficial effects on the lethality of HIV infection due to vertical transmission",
abstract = "D-penicillamine (DPA) was first recognized as a potential benefit for neonatal hyperbilirubinemia (NHBI). During this time there was a remarkedly low incidence of retinopathy of prematurity (ROP) in the infants treated with DPA. Later, our studies were replicated in other institutes in Hungary, Poland, the U.S. A., India and Mexico. It is important to note that there was no intolerance or short- or long-term toxicity of the medication, in spite of the fact that in the newborn period DPA was used 10-20 times higher doses than those in adult. On the basis of an American research work concerning the beneficial effects of DPA-therapy in adult AIDS-patients (although in these cases there were many unpleasant, adverse effects), it would be reasonable to treat neonatal HIV-positivity due to vertical transmission with short-term DPA therapy (300 - 400 mg/kg/bw/day for 5-7 days). Therefore, we have a moral obligation to help the fight against HIV with this inexpensive (~ 30 USD/baby) drug in the neonatal period.",
keywords = "D-penicillamine, HIV/AIDS therapy, Neonatal hyperbilirubinemia, Retinopathy of prematurity",
author = "G. Balla and Lajos Lakatos and Istv{\'a}n Pataki and Zsuzsanna Vekerdy-Nagy and Gy{\"o}rgy Oroszl{\'a}n",
year = "2015",
month = "7",
day = "1",
language = "English",
volume = "33",
pages = "30--42",
journal = "International Journal of Pharmaceutical Sciences Review and Research",
issn = "0976-044X",
publisher = "Global Research Online",
number = "2",

}

TY - JOUR

T1 - D-penicillamine in the neonatal period

T2 - Possible beneficial effects on the lethality of HIV infection due to vertical transmission

AU - Balla, G.

AU - Lakatos, Lajos

AU - Pataki, István

AU - Vekerdy-Nagy, Zsuzsanna

AU - Oroszlán, György

PY - 2015/7/1

Y1 - 2015/7/1

N2 - D-penicillamine (DPA) was first recognized as a potential benefit for neonatal hyperbilirubinemia (NHBI). During this time there was a remarkedly low incidence of retinopathy of prematurity (ROP) in the infants treated with DPA. Later, our studies were replicated in other institutes in Hungary, Poland, the U.S. A., India and Mexico. It is important to note that there was no intolerance or short- or long-term toxicity of the medication, in spite of the fact that in the newborn period DPA was used 10-20 times higher doses than those in adult. On the basis of an American research work concerning the beneficial effects of DPA-therapy in adult AIDS-patients (although in these cases there were many unpleasant, adverse effects), it would be reasonable to treat neonatal HIV-positivity due to vertical transmission with short-term DPA therapy (300 - 400 mg/kg/bw/day for 5-7 days). Therefore, we have a moral obligation to help the fight against HIV with this inexpensive (~ 30 USD/baby) drug in the neonatal period.

AB - D-penicillamine (DPA) was first recognized as a potential benefit for neonatal hyperbilirubinemia (NHBI). During this time there was a remarkedly low incidence of retinopathy of prematurity (ROP) in the infants treated with DPA. Later, our studies were replicated in other institutes in Hungary, Poland, the U.S. A., India and Mexico. It is important to note that there was no intolerance or short- or long-term toxicity of the medication, in spite of the fact that in the newborn period DPA was used 10-20 times higher doses than those in adult. On the basis of an American research work concerning the beneficial effects of DPA-therapy in adult AIDS-patients (although in these cases there were many unpleasant, adverse effects), it would be reasonable to treat neonatal HIV-positivity due to vertical transmission with short-term DPA therapy (300 - 400 mg/kg/bw/day for 5-7 days). Therefore, we have a moral obligation to help the fight against HIV with this inexpensive (~ 30 USD/baby) drug in the neonatal period.

KW - D-penicillamine

KW - HIV/AIDS therapy

KW - Neonatal hyperbilirubinemia

KW - Retinopathy of prematurity

UR - http://www.scopus.com/inward/record.url?scp=84940539103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940539103&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 30

EP - 42

JO - International Journal of Pharmaceutical Sciences Review and Research

JF - International Journal of Pharmaceutical Sciences Review and Research

SN - 0976-044X

IS - 2

M1 - 07

ER -